Omnicell, Inc. $OMCL Shares Sold by Trexquant Investment LP

Key Points

• Trexquant Investment LP reduced its stake in Omnicell, Inc. by 47.6% in the first quarter, selling 27,311 shares and retaining 30,053 shares valued at approximately $1,051,000.
• Several hedge funds have altered their stakes in Omnicell, with Lazard Asset Management LLC increasing its stake by 81.6% and acquiring a total of 1,641,817 shares.
• Omnicell's stock price decreased by 3.0%, with the company reporting better-than-expected quarterly earnings of $0.45 per share, surpassing analysts' forecasts of $0.30.

Trexquant Investment LP lowered its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 47.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,053 shares of the company's stock after selling 27,311 shares during the quarter. Trexquant Investment LP owned approximately 0.06% of Omnicell worth $1,051,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Diversified Trust Co grew its holdings in Omnicell by 2.3% in the first quarter. Diversified Trust Co now owns 22,660 shares of the company's stock worth $792,000 after purchasing an additional 513 shares during the last quarter. Bridge City Capital LLC grew its holdings in Omnicell by 1.6% in the first quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock worth $1,403,000 after purchasing an additional 650 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Omnicell by 4.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company's stock worth $553,000 after purchasing an additional 696 shares during the last quarter. EntryPoint Capital LLC grew its holdings in Omnicell by 21.6% in the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock worth $233,000 after purchasing an additional 1,184 shares during the last quarter. Finally, Wakefield Asset Management LLLP grew its holdings in Omnicell by 8.1% in the first quarter. Wakefield Asset Management LLLP now owns 25,517 shares of the company's stock worth $892,000 after purchasing an additional 1,906 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on OMCL. Wells Fargo & Company lifted their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Piper Sandler cut their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Bank of America upped their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Stock Performance

NASDAQ OMCL traded down $0.91 on Wednesday, reaching $31.86. 512,120 shares of the company's stock traded hands, compared to its average volume of 564,459. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 63.72, a P/E/G ratio of 7.06 and a beta of 0.82. The stock has a 50 day moving average price of $30.55 and a 200-day moving average price of $31.21. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm's revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.